CMBA
RETA

C.M. Bidwell & Associates’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

C.M. Bidwell & Associates’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,450
Closed -$51K – 472
2018
Q2 		$51K Buy
+1,450
New +$44.2K 0.05% 243

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

C.M. Bidwell & Associates's RETA Position: Q3 2018 in Review

C.M. Bidwell & Associates sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2018, closing a stake of 1,450 shares — an estimated $51K sold.

C.M. Bidwell & Associates first reported a position in RETA in Q2 2018 and held it in 1 quarter. The position peaked at $51K in Q2 2018. 119 funds tracked by Wall St. Rank hold RETA as of Q3 2018.

  • C.M. Bidwell & Associates reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2018 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,450 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2018, an estimated $51K.
  • C.M. Bidwell & Associates first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $51K in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.